Conversion from calcineurin inhibitors to mTOR inhibitors

Current Opinion in Organ Transplantation

Volumn 12, Issue 4, 2007, Pages 351-356

  Bodziak, Kenneth A ^a   Hricik, Donald E ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Calcineurin inhibitor; Chronic allograft nephropathy; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TACROLIMUS;

ANEMIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; DIARRHEA; DRUG SAFETY; EDEMA; FOLLOW UP; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HIRSUTISM; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MOUTH ULCER; NEPHROTOXICITY; PNEUMONIA; PROTEIN URINE LEVEL; PROTEINURIA; RENAL GRAFT DYSFUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; TASTE DISORDER; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

EID: 34447536218     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32819f8ef4     Document Type: Review

References (60)

1. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50:235-242.
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of first cadaveric transplants. N Engl J Med 1999; 341:1725-1730.
3. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4:655-662.
4. Weir MR, Blahut S, Drachenburg C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24:379-386.
5. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777-786.
6. Gonwa TA, Hricik DE, Brinker K, et al. Sirolimus Renal Function Study Group: improved renal function in sirolimus treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74:1560-1567.
7. Groth CG, Backman L, Morales JM, et al. Sirolimus (Rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036-1042.
8. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252-1260.
9. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74:1770-1776.
10. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4:1776-1785.
11. Larson TS, Dean PG, Stegall M, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514-522.
12. Marcen R, Chahin J, Alarcon A, Bravo J. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. Transplant Proc 2006; 38:2427-2430.
13. Cheung CY, Wong KM, Chan HW, et al. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients. Transpl Int 2006; 19:657-666.
14. Gelens MA, Christiaans MH, van Hoof JP. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus? Transplant Proc 2005; 37:1900-1901.
15. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178-185.
16. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3:590-598.
17. MacDonald AS. Impact of immunosuppressive therapy on hypertension. Transplantation 2000; 70 (11 Suppl):S70-S76.
18. Cauduro RL, Costa C, Lhulier F, et al. Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin Transplant 2005; 19:470-474.
19. Hricik DE. Hyperlipidemia in renal transplant recipients. Graft 2000; 3:11-19.
20. van Duijnhoven EM, Christiians MH, Boots JM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002; 13:213-220.
21. Barton CH, Vaziri ND. Cyclosporine nephrotoxicity. Int J Artif Organs 1985; 8:291-296.
22. Ahuja SS, Shrivastav S, Danielpour D, et al. Regulation of transforming growth factor-β and its receptor by cyclosporine in human T lymphocytes. Transplantation 1995; 60:718-723.
23. Wolf G, Thaiss F, Stahl RAK. Cyclosporine stimulates expression of transforming growth factor-β in renal cells. Transplantation 1995; 60:237-241.
24. Shihab FS, Bennett WM, Hong Y, et al. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-β1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003; 3:1550-1559.
25. Halloran PF, Melk A, Bath C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10:167-173.
26. Ojo AO, Held PJ, Port FK, et al. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333-346.
27. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333.
28. Neuhas P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001; 7:473-484.
29. Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999; 68:1526-1532.
30. MacDonald AS. A worldwide phase III randomised, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71:271-280.
31. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporine, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16:121-124.
32. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59:3-16.
33. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5:2273-2280.
34. Dodge IL, Demirici G, Strom TB, Li XC. Rapamycin induces transforming growth factor-β production by lymphocytes. Transplantation 2000; 70:1104-1106.
35. Shihab FS, Bennett WM, Hong Y, et al. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-β1. Transplantation 2004; 77:683-686.
36. Ikonen TS, Gummert JF, Serkova N, et al. Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in nonhuman primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int 2000; 13 (Suppl 1):S314-S320.
37. deMattaos AM, Olyai AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333-346.
38. Kaplan B, Schold J, Srinivas T, et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant 2004; 4:1709-1712.
39. Augustine JJ, Chang PC, Knauss TC, et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation 2006; 81:1004-1009.
40. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16:3755-3762.
41. Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based versus calcineurin inhibitorbased immunosuppression in live donor kidney transplantation. Transplantation 2006; 82:368-374. This study is one of the first to suggest that sirolimus may cause proteinuria independent of treatment with calcineurin inhibitors.
42. Oberbauer R, Schena FP, Wali R, et al. Conversion from caclineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24-month safety and efficacy results from the CONVERT trial [abstract]. J Am Soc Nephrol 2006; 17:69A. This abstract summarizes the important outcomes of the CONVERT trial, the largest currently active randomized trial of CNI-to-sirolimus conversion
43. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82:1153-1162. A meta-analysis of randomized and nonrandomized trials that forms the primary basis for the current review.
44. Watson CJE, Firth JE, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5:2496-2503.
45. Baboolal K. Six month interim analysis of a phase III prospective, randomised study to compare conversion from calcineurin inhibitors to rapamycin in established renal allograft recipients with mild to moderate renal insufficiency [abstract]. Am J Transplant 2004; 4 (S8):220.
46. Paczek L, Dedocova J, Matl I, Ohanka E. An open non comparative pilot study of renal function after conversion from cyclosporine to sirolimus in stable renal allograft recipients with mild to moderate renal insufficiency [abstract]. Am J Transplant 2003; 3 (Suppl 5):217.
47. Peddi VR, Jensik S, Pescovitz M, et al. An open-label pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19:130-136.
48. Wali RK, Richards A, Cunningham R, et al. Can we change the progressive decay in graft function after the onset of chronic allograft nephropathy in the recipients of kidney allografts? [abstract]. Am J Transplant 2003; 3 (S5):336.
49. Moneim HA, Fletchner SM, George P, et al. Conversion to and from sirolimus in renal and hepatic transplant recipients treated with calcineurin inhibitors: effect on renal function [abstract]. Am J Transplant 2005; 5 (S11):376.
50. Hoecker N, Feneberg R, Koepf S, et al. Switch of immunosuppression from calci9neurin inhibitors to sirolimus in pediatric renal transplant recipients with CNI toxicity [abstract]. Am J Transplant 2005; 5 (S11):497.
51. Bumbea V, Kamar N, Ribes D, et al. Lonf term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20:2517-2523.
52. Crowley KL, Hardinger KL, Koch M, et al. A single center experience with sirolimus conversion therapy in renal allograft recipients [abstract]. Am J Transplant 2003; 3 (S5):354.
53. Diekmann F, Waiser J, Fritsche L, et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor induced nephrotoxicity. Transplant Proc 2001; 33:3234-3235.
54. Egidi MF, Cowan PA, Naser A, Gaber AO. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 2003; 35:131S-137S.
55. Hadaya K, Wissing M, Broeders N, Abramaowicz D. Nephrotic range proteinuria and other severe adverse events after conversion to sirolimus in renal transplantation: is high exposure to sirolimus responsible? [abstract]. Am J Transplant 2004; 4 (S8):433.
56. Lacha J, Bartosova K, Matl I, et al. Sirolimus associated proteinuria. Study in kidney and heart recipients after calcineurin inhibitor withdrawal and in kidney transplant recipients with sirolimus de novo immunosuppression. [abstract]. Am J Transplant 2005; 5:414.
57. Renders L, Steinbach R, Valerius T, et al. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press 2004; 27:181-185.
58. Citterlo F, Scata MC, Violo P, et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003; 35:1292-1294.
59. Teutonico A, Schena PF, Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16:3128-3135.
60. Van Gelder T, ter Muelen CG, Hene R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75:788-792.